secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001628280-24-045998
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE reports Q3 net loss $12.2M; VYN201 Phase 2b enrollment exceeds target, top-line mid-2025
--------------------------------------------------------------------------------

- Net loss of $12.2M ($0.29/sh) in Q3 2024 vs $6.6M ($2.01/sh) in Q3 2023, driven by higher R&D spend.
- Cash and marketable securities of $70.2M; expected to fund operations through end of 2025.
- VYN201 Phase 2b vitiligo trial enrollment exceeded target; fully enrolled Dec 2024, top-line mid-2025.
- VYN202 Phase 1a SAD data positive; MAD data expected Q4 2024. Plans for Phase 1b in psoriasis and RA.
- R&D expenses rose 208.9% to $10.2M due to advancing clinical trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000162828024045998/0001628280-24-045998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000162828024045998/mnlo-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-045998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer